Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Stock Chart & Stats
$17.03
$1.44(1.16%)
At close: 4:00 PM EST
$17.03
$1.44(1.16%)
Day’s Range― - ―
52-Week Range$10.42 - $114.41
Previous CloseN/A
Volume185.86K
Average Volume (3M)2.58M
Market Cap
$2.07B
Enterprise Value$2.57B
Total Cash (Recent Filing)$850.99M
Total Debt (Recent Filing)$1.25B
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Mar 03, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding104,787,186
10 Day Avg. Volume3,009,943
30 Day Avg. Volume2,582,654
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.57
Price to Sales (P/S)6.08
P/FCF Ratio-32.77
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue1.07
Enterprise Value/Gross Profit1.40
Enterprise Value/Ebitda-14.25
Forecast
1Y Price Target
$22.47Price Target Upside31.94% Upside
Rating ConsensusHold
Number of Analyst Covering18
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Strategy And Physician PerceptionManagement plans to relaunch the commercial campaign with a substantially larger salesforce and targeted clinical initiatives, which analysts expect to change physician and patient perception and increase Elevidys uptake.
Immunosuppression StrategyAnalyst highlights evidence that prophylactic sirolimus reduced acute liver injury versus steroid-only approaches, supporting enhanced immunosuppression protocols to improve Elevidys safety and broaden patient eligibility.
Pipeline Upside And OptionalityAnalyst points to positive early-phase data from FSHD, DM1, and early-stage siRNA programs as upside optionality that could expand the company’s valuation beyond the core Duchenne franchise.
Bears Say
Commercial Headwinds And CompetitionAnalyst emphasizes weak commercial momentum and increasing competition for exon-skipping products, suggesting sales growth may remain modest without further de-risking or broader pipeline successes.
Regulatory Pathway RiskAnalyst notes that plans to pursue traditional approvals for exon-skipping therapies, combined with expectations that regulators will request additional data, create approval risk that could slow full market access.
Trial Design And Control IntegrityAnalyst warns that removal of the randomized placebo control and reliance on an external control undermines confidence in efficacy comparisons and weakens the evidentiary basis for durable treatment claims.
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $10.41 and its highest was $114.41 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $2.07B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 24 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Nov 03, 2025. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of -$0.727 by -$1.073.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is -1.2.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 104,787,186 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of -$1.8 in its last earnings report, missing expectations of -$0.727. Following the earnings report the stock price went down -33.742%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sarepta Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.47 (31.94% Upside)
$22.47 (31.94% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 638.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $294.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.69%
12-Months-Change
Fundamentals
Return on Equity
-21.37%
Trailing 12-Months
Asset Growth
-2.96%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
SRPT Company Deck
SRPT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view, with significant achievements in revenue and study completions, alongside challenges such as the ESSENCE trial missing statistical significance and disruptions from paused shipments.View all SRPT earnings summariesSRPT Stock 12 Month Forecast
Average Price Target
$22.47
▲(31.94% Upside)
Technical Analysis
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―
Ownership Overview
5.23% Insiders
14.37% Mutual Funds
0.02% Other Institutional Investors
53.50% Public Companies and Individual Investors